



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: RU-0191

Inventors: Conney et al.

Serial No.: 10/657,685

Filing Date: September 8, 2003

Examiner: Delacroix Muirhei, Cybille

Group Art Unit: 1614

Title: Compositions and Methods for Inhibiting
Proliferation in Human Prostate Cancer
Cells

"Express Mail" Label No. EV735453164US
Date of Deposit JULY 8, 2005

I hereby certify that this paper is being deposited with the
United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to Mail Stop Fee
Amendment, Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450.

By Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

Mail Stop Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION TO CORRECT INVENTORSHIP
UNDER 37 C.F.R. §1.48(b)

Petition is hereby made to correct inventorship of the above-
referenced patent application in accordance with 37 C.F.R.

07/13/2005 SSITHIB1 00000120 501619 10657685
02 FC:1464 130.00 DA


§1.48(b). The patent application as originally filed named Allan H. Conney as a sole inventor.

Xi Zheng, through collaboration contributed conceptually to the studies on the effects of TPA alone and in combination with all-trans retinoic acid on prostate cancer.

Therefore, Xi Zheng should have been named as an inventor. Attached are the executed Declarations of Xi Zheng and Allan H. Conney in support thereof.

Authorization to charge Deposit Account #50-1619 the amount of \$130.00 is enclosed, as set forth in 37 C.F.R. 1.17(I). Please charge any deficiency or credit any overpayment to Deposit Account #50-1619.

Respectfully submitted,



Jane Massey Licata
Registration No. 32,257

Date: JULY 8, 2005

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: RU-0191
Inventors: Conney, Allan H.
Serial No.: 10/657,685
Filing Date: September 8, 2003
Examiner: Delacroix Muirheir, Cybille
Customer No.: 26259
Group Art Unit: 1614
Confirmation No.: 1261
Title: Compositions and Methods for Inhibiting Proliferation in Human Prostate Cancer Cells

"Express Mail" Label No. EV735453184US
Date of Deposit: 7-8-05

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Mail Stop Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: [Signature]
Typed Name: Jane Massey Lenta, Reg. No. 32,257

Mail Stop Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF ALLAN H. CONNEY

I, Allan H. Conney hereby declare and state that:

1. I am a co-author along with Xi Zheng, Richard L. Chang, Xiao-Xing Cui, Kathleen A. Kelly, Weichung Joe Shih, Yong Lin, Roger Strair, Junghan Suh, Zheng Tao Han, and Arnold Rabson of the paper entitled "Synergistic Effects of Clinically Achievable Concentrations of 12-O-Tetradecanoylphorbol-13-acetate in

Attorney Docket No.: RU-0191
Inventors: Conney, Allan H.
Serial No.: 10/657,685
Filing Date: September 8, 2003
Page 2

Combination With all-trans Retinoic Acid, 1 α ,25-Dihydroxyvitamin D₃, and Sodium Butyrate on Differentiation in HL-60 Cells" published on-line on October 20, 2001 and in print on November 8, 2001 in the journal Oncology Research.

2. I am a co-inventor in U.S. Patent Application Serial No. 10/657,685 filed September 8, 2003 and am most familiar with the subject matter of this application and the research effort which lead to the discovery of the instant invention.

3. A petition to include co-author Xi Zheng as co-inventor in U.S. Patent Application Serial No. 10/657,685 is submitted herewith.

4. The roles of the co-authors Richard L. Chang, Xiao-Xing Cui, Kathleen A. Kelly, Weichung Joe Shih, Yong Lin, Roger Strair, Junghan Suh, Zheng Tao Han, and Arnold Rabson are as follows:

Richard L. Chang was a faculty member who advised concerning the design of some of the experiments disclosed in the paper.

Xiao-Xing Cui was a laboratory assistant in my laboratory working under my direction who conducted some of the experiments involving cell cultures, the data of which are disclosed in the paper.

Kathleen A. Kelly was an undergraduate student in my laboratory learning about scientific research, who contributed to the cell culture studies, the data of which are disclosed in the paper.

Weichung Joe Shih, from the Cancer Institute of New Jersey, assisted with the statistical analysis associated with the research conducted in my laboratory, the data of which are disclosed in the paper.

Attorney Docket No.: RU-0191
Inventors: Conney, Allan H.
Serial No.: 10/657,685
Filing Date: September 8, 2003
Page 3

Yong Lin, from the Cancer Institute of New Jersey, assisted with the statistical analysis associated with the research conducted in my laboratory, the data of which are disclosed in the paper.

Roger Strair, from the Cancer Institute of New Jersey, was a clinical consultant concerning the data disclosed in the paper.

Junghan Suh was a graduate student in Arnold Rabson's laboratory, who together with Dr. Rabson, provided advice on the potential role of NFkB in differentiation and apoptosis in HL-60 cells, the data of which are disclosed in the paper.

Zheng Tao Han was a consultant located in China, who discussed with me the clinical significance of the data disclosed in the paper.

Arnold Rabson, from the Cancer Institute of New Jersey, provided advice on potential role of NFkB in differentiation and apoptosis in HL-60 cells, the data of which are disclosed in the paper.

While their assistance was a tremendous aid to obtaining the data disclosed in this paper, they did not contribute to the concept and did not contribute any inventorship to the reduction to practice of the invention claimed in U.S. Application Serial No. 10/657,685. Richard L. Chang, Xiao-Xing Cui, Kathleen A. Kelly, Weichung Joe Shih, Yong Lin, Roger Strair, Junghan Suh, Zheng Tao Han, and Arnold Rabson were properly designated as co-authors in view of their roles in generating and analyzing data disclosed in the publication.

I hereby declare that all statements herein of our own knowledge are true and that all statements made on information or belief are believed to be true; and further that these statements were made with the knowledge that willful statements and the like

BEST AVAILABLE COPY

- MAIN

01005

Attorney Docket No.: RU-0191
Inventors: Conney, Allan H.
Serial No.: 10/657,685
Filing Date: September 8, 2003
Page 4

so made are punishable by fine or by imprisonment, or both, under
1001 of Title 18 of the United States Code, and that such willful
statements may jeopardize the validity of the application, any
patent issuing there upon, or any patent to which this verified
statement is directed.

Allan H. Conney
Dr. Allan H. Conney

July 7, 2005
Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: RU-0191

Inventors: Conney et al.

Serial No.: 10/657,685

Filing Date: September 8, 2003

Examiner: Delacroix Muirhei, Cybille

Group Art Unit: 1614

Title: Compositions and Methods for Inhibiting Proliferation in Human Prostate Cancer Cells

Express Mail® Label No. EV735453164US
Date of Deposit JULY 8, 2005

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

Mail Stop Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF XI ZHENG

I, Xi Zheng hereby declare that:

1. I was not named as an inventor on the above-referenced application when the application was filed. I contributed conceptually to the studies on the effects of TPA alone and in

combination with all-trans retinoic acid on prostate cancer and therefore should have been named as an inventor.

2. This error occurred without any deceptive intention on my part.

I hereby declare that all statements herein of my own knowledge are true and that all statements made on information or belief are believed to be true; and further that these statements were made with the knowledge that willful statements and the like so made are punishable by fine or by imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful statements may jeopardize the validity of the application, any patent issuing there upon, or any patent to which this verified statement is directed.

Xi Zheng
Xi Zheng

Dated: 1.20.2005